君实生物：JT118 注射液获药物临床试验批准通知书

Core Viewpoint - Junshi Bioscience announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of the JT118 injection, a recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Group 1 - The clinical trial application for JT118 has been approved, indicating progress in the development of this vaccine [1] - JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 and M1, highlighting its innovative approach to vaccine development [1]